Close

Press Releases

Global Experts to Share HIV/AIDS Updates, Trends at July 30 Event in Washington, DC

Distinguished experts and practitioners at the forefront of global HIV programs research and policy will present emerging trends and potential breakthrough strategies at a special event on July 30 in Washington D.C. Creative Associates International announced. ...

Novaliq GmbH Announces European Market Approval for NovaTears™ OTC

Novaliq GmbH a drug delivery company with a focus on the topical application of ophthalmic technologies for poorly soluble drugs today announced the successful CE mark approval for the first topical eye lubricant based on Novaliq’s proprietary technology EyeSol™....

Investment Group Acquires Metrics Champion Consortium to Drive Adoption and Growth

The Metrics Champion Consortium (MCC) board of directors announced today that the organization has been sold to a group of investors. The existing non-profit MCC will discontinue and a Limited Liability Corporate structure will take...

Oncodesign awarded accreditation of its research center by international association, AAALAC

Oncodesign, a contract research laboratory for the discovery of new anticancer therapies, today announces that its Dijon-based research center has received AAALAC certification.  AAALAC, the Association for Assessment and Accreditation of Laboratory Animal Care International,...

Cubist Enrolls First Patient in Phase 3 Efficacy Studies Evaluating Bevenopran for the Treatment of Opioid-Induced Constipation

Cubist Pharmaceuticals Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC). The Phase 3 program ASCENT includes three...

Alize Pharma launches the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes

Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2...

Impax Laboratories Launches Authorized Generic TRILIPIX® Delayed Release Capsules, 45 mg and 135 mg

Impax Laboratories Inc. today announced that it is commencing shipment of authorized generic TRILIPIX® (fenofibric acid) delayed release capsules 45 mg and 135 mg through Global Pharmaceuticals Impax’s generics division. Under the terms of a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »